The role of somatostatin analogues in the treatment of refractory diarrhoea

Digestion

Volumn 57, Issue , 1996, Pages 107-113

  Farthing, Michael J G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AIDS; Bowel; Carcinoma; Diabetes; Diarrhoea; Graft versus host disease; Octreotide; Sclerosis; Somatostatin; VIPoma

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER CHEMOTHERAPY; CARCINOID; CONFERENCE PAPER; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SECRETION; GRAFT VERSUS HOST REACTION; HUMAN; INTESTINE MOTILITY; NEUROENDOCRINE TUMOR; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; SHORT BOWEL SYNDROME; SYSTEMIC SCLEROSIS;

ANIMALS; DIARRHEA; DRUG RESISTANCE; GASTROINTESTINAL AGENTS; HORMONE ANTAGONISTS; HUMANS; OCTREOTIDE; SOMATOSTATIN;

EID: 0029946788     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201412     Document Type: Article

References (52)

1. Schiller LR, Hogan RB, Morawski SG, Santa Ana CA, Bern MJ, Norgaard RP, Bo-Linn GW, Fordtran JS: Studies of the prevalence and significance of radiolabelled bile acid malabsorption in a group of patients with idiopathic chronic diarrhoea. Gastroenterology 1987:92: 151-160.
2. O'Donnell LJD, Watson AJM, Cameron D, Farthing MJG: Effect of octreotide on mouth-to-caccum transit time in healthy subjects and the irritable bowel syndrome. Aliment Pharmacol Ther 1990:4:177-182.
3. Harris AG: Octreotide in the treatment of disorders of the gastrointestinal tract. Drug Invest 1992;4(suppl 3): 1-54.
4. Nightingale JMD, Lennard-Jones JE, Walker ER, Farthing MJG: Jejunal efflux in short bowel syndrome. Lancet 1990;336:765-768.
5. Rodrigues CA, Lennard-Jones JE, Thompson DG, Farthing MJG: The effects of octreotide, soy polysaccharide, codeine and loperamide on nutrient, fluid and electrolyte absorption in the short bowel syndrome. Aliment Pharmacol Ther 1989:3:159-169.
6. Dharmsathaphorn K, Gorelick FS, Shcrwin RS, Cataland S, Dobbins JW: Somatostatin decreases diarrhoea in patients with the short bowel syndrome. J Clin Gastroenterol 1982:4: 521-524.
7. Williams NS, Cooper JC, Axon ATR, King RFGJ, Barker M: Use of a long-acting somatostatin analogue in controlling life threatening ileostomy diarrhoea. Br MedJ 1984:289:1027-1028.
8. Cooper JC, Williams NS, Kingd RFGI, Barker MCJ: Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea. Br J Surg 1986:73:128-131.
9. Nightingale JMD, Walker ER, Burnham WR, Farthing MJG, Lennard-Jones JE: Octreotide (a somatostatin analogue) improves the quality of life in some patients with a short intestine. Aliment Pharmacol Ther 1989:3:367-373.
10. Ladefoged K, Christensen KC, Hegnhoj J, Jarnum S: Effect of a long-acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome. Gut 1989:30:943-949.
11. Ohlbaum P, Galpcrinc RI, Démarquez IL, Vergnes P, Martin C: Use of long-acting somatostatin analogue (SMS 201-995) in controlling a significant ileal output in a 5 year old child. J Pediatr Gastroenterol Nutr 1987:6:466-470.
12. Lamireau T, Galperinc RI, Ohlbaum P, Démarquez JL, Vergnes P, Kurzcnne Y, He-hunstre JP: Use of a long-acting somatostatin analogue in controlling Ileostomy diarrhoea in infants. Acta Paediatr Scand 1990;79:871-872.
13. Nightingale JMD, Walker ER, Farthing MJG, Lennard-Jones JE: Effect of omeprazole on intestinal output in the short bowel syndrome. Aliment Pharmacol Ther 1991:5:405-412.
14. Cascinu S, Fedeli A, Fedeli SL, Catalano G: Control of chcmotherapv-induccd diarrhoea with octreotide in patients receiving 5-fluoro-uracil. Eur J Cancer 1992;28:482-483.
15. Petrelli NJ, Rodriguez-Bigas M, Rustum Y, Herrera L, Crcaven P: Bowel rest, intravenous hydration and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. Cancer 1993:72:1543-1546.
16. Cascinu S, Fedeli A, Fedeli SL, Catalano G: Control of chemotherapy-induced diarrhea with octreotide: A randomized trial with placebo in patients receiving cisplatin. Oncology 1994:51:70-73.
17. Gebbia V, Larreca I, Testa A, Valenza R, Curto G, Cannata G, Borsellino N, Latteri MA, Cipolla C, Folorcna M, et al.: Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993;4:443-445.
18. Cascinu S, Fedeli A, Fedeli SL, Catalano G: Octreotide versus loperamide in the treatment of lluorouracil-induced diarrhea: A randomized trial. J Clin Oncol 1993; 11:148-151.
19. Wadler S, Haynes H, Wiernik PH: Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995; 13:222-226.
20. Couper RTL, Berzen A, Bcrall G, et al.: Clinical response to the long acting somatostatin analogue octreotide in a child with congenital microvillus atrophy. Gut 1989;30:1020-1024.
21. Ruskonc A, Rene E, Chayviallc JA, et al.: Effect of somatostatin on diarrhoea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 1982:27:459-466.
22. Maton PM, O'Dorisio TM, Howe BA, et al.: Effect of long-acting somatostatin analogue (octreotide) in patients w ith pancreatic cholera. N Engl J Med 1985:312:17-21.
23. Santangelo WC, Ducno MI, Krejs BJ: Pseudo-pancreatic cholera syndrome: EITcct of a synthetic somatostatin analogue, SMS 201-995. Am J Med 1987;82:84-87.
24. Eriksson B, Oberg K, Andcrsson T, et al.: Treatment of malignant endocrine pancreatic tumours with a new long-acting somatostatin analogue, octreotide. Scand J Gastroenterol 1988:23:508-512.
25. Gorden P, Comi RJ, Maton PN, et al.: Somatostatin and somatostatin analogue (SMS 201-995) in the treatment of hormone-secreting tumours of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intent Med 1989:110:35-50.
26. Dharntsathaphorn K, Shcrwin RS, Cataland S, et al.: Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980:92: 68-69.
27. Richter G, Stockmann B, Conlon JM, et al.: Short-term administration of the somatostatin analogue octreotide in patients with carcinoid tumours. Scand J Gastroenterol 1986:21:193S.
28. Souquct JC, Sassolas G, Forichon J, et al.: Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987.59:1654-1660.
29. Kvols LK, Moertcl CG, O’Connell MJ, et al.: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986:315:663-666.
30. Vinik AI, Moattari AR: Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sei 1989:34(suppl): 14-27.
31. Chayvialle JA: Sandostatin and carcinoid tumours in France: Experience in the Lyon area. Digestion 1990:40(suppl I):23-26.
32. Woods HF, Bax NDS, Ainsworth I: Abdominal carcinoid tumours in Sheffield. Digestion 1990;4(suppl I): 17-22.
33. Smith S, Anthony L, Roberts LJ, et al.: Resolution of musculo-skelctal symptoms in the carcinoid syndrome after treatment with the somatostatin analog octreotide. Ann Intern Med 1990:112:66-68.
34. Vinik AI, Tsai ST, Moattari AR, et al.: Somatostatin analogue (SMS 201-995) in the management of gaslroenteropancreatic tumors and diarrhea syndromes. Am J Med 1986;81 (suppl 6B):23-40.
35. Mozell E, Woltering EA, O’Dorisio TM, et al.: Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome. Surg Gynecol Obstct 1990:170: 476-484.
36. Smid WM, Dullaart RP: Octreotide for medullary thyroid carcinoma associated diarrhoea. Nelli J Med 1992:40:240-243.
37. Cello JP, Grcndell J, Basuk P, Simon D, Weiss L, Rood R, Wilcox CM, Forsmark C, Read A, Satow JA, Weikel CS, Beaumont C: Controlled clinical trial of octreotide for refractory A1DS-associalcd diarrhoea. Gastroenterology 1990; 98(suppl 1):A163.
38. Cello JP, Grcndell JH, Basuk P, Simon D, Weiss L, Winner M, Rood RP, Wilcox CM, Forsmark CE, Read AE, et al.: Effect of octreotide on refractory AIDS-associated diarrhea: A prospective, multicenter clinical trial. Ann Intern Med 1991:115:705-710.
39. Garcia Copmean D, Ramos Jimenez J, Guzman G, de la Garza F, Saenz C, Maldonado H, Barragan RF, Michel H: Octreotide therapy of large-volume refractory AIDS-associated diarrhea: A randomized controlled trial. AIDS 1994:8:1563-1567.
40. Simon DM, Cello JP, Valenzuela J, Levy R, Dickerson G, Goodgame R, Brown M, Lyche K. Fesscl WJ, Grendell J, Wilcox CM, Afdhal N, Fogel R, Reeves-Darby V, Stern J. Smith O, Graziano F, Plcakow D, Flanagan T, Schubert T, Loveless M, Eron L, Basuk P, Bonacini M, Orenstein J: Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995;108:1753-1760.
41. Bianco JA, Higano C, Singer J, et al.: The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-vcrsus-host disease in a patient after bone marrow transplantation. Transplantation 1990:49:1194-1195.
42. Ely P, Dunitz J, Rogosheskc J, Weisdorf D: Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft versus host disease. Am J Med 1991; 90:707-710.
43. Tsai ST, Vinik AI, Brunner JF: Diabetic diarrhoea and somatostatin. Ann Intern Med 1986; 104:894.
44. Dudl RJ, Anderson DS, Forsythe AB, et al.: Treatment of diabetic diarrhea and orthostatic hypotension with somatostatin analogue octreotide. Am J Med 1987:83:584-588.
45. Mourad FH, Gorard D, Thillainayagant AV, Colin-Jones D, Farthing MJG: Effective treatment of diabetic diarrhoea with the somatostatin analogue, octreotide. Gut 1992:33:578-580.
46. Nakabayashi H, Fujii S. Miwa U, Seta T, Takeda R: Marked improvement of diabetic diarrhea with the somatostatin analogue octreotide. Arch Intern Med 1994:154:1863-1867.
47. Walker JJ, Kaplan DS: Efficacy of the somatostatin analog octreotide in the treatment of two patients with refractory diabetic diarrhea. Am J Gastroenterol 1993:88:765-767.
48. Dean AP, Reed WD: Diarrhoea - An unrecognized hazard of coeliac plexus block. Aust NZ J Med 1991;21:47-48.
49. Soudah HC, Hasler WL, Owyang CH: Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991:325:1461-1467.
50. Talley NJ, Turner I, Middleton WR: Somatostatin and symptomatic relief of irritable bowel syndrome. Lancet 1987;ii:1114.
51. O’Donnell LJ, Wass JA, Farthing MJG: Plasma somatostatin concentrations in irritable bowel syndrome. Aliment Pharmacol Ther 1991:5:659-663.
52. Hasler WL, Soudah HC, Owyang C: Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994; 268:1206-1211.